

CLAIMS

1. A method of treating multiple sclerosis (MS), including the step of administering to an individual a pharmaceutically-effective amount of cpn10 and IFN- β .
- 5 2. The method of Claim 1, when used as a treatment to prevent relapse of MS.
3. The method of Claim 1 or Claim 2, wherein IFN- β and cpn10 are administered together.
- 10 4. The method of Claim 1 or Claim 2, wherein IFN- β and cpn10 are administered separately.
5. The method of Claim 3, wherein IFN- β and cpn10 are administered by injection.
6. The method of Claim 4, wherein cpn10 is administered orally.
7. The method of Claim 4 or Claim 6, wherein IFN- β is administered by injection.
- 15 8. The method of Claim 1 or Claim 2, wherein the pharmaceutically effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10.
9. The method of Claim 8, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 10-30 mg of cpn10.
- 20 10. The method of Claim 1 or Claim 2, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1'-10 Million International Units (MIU) of IFN- β .
11. The method of Claim 10, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 4-6 MIU of IFN- β .
- 25 12. A pharmaceutical composition for treating MS, said composition comprising a pharmaceutically-effective amount of cpn10 and IFN- β and a pharmaceutically-acceptable carrier or diluent.
13. The composition of Claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10.
- 30 14. The composition of Claim 13, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 10-30 mg of cpn10.

15. The composition of Claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1-10 MIU of IFN- β .

16. The composition of Claim 15, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 4-6 MIU of IFN- β .

5 17. A kit comprising a pharmaceutically-effective amount of cpn10 and IFN- β and a pharmaceutically-acceptable carrier or diluent.

Sub B1

18. The kit of Claim 17, wherein said IFN- β is in dehydrated form, which in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

10 19. The kit of Claim 18, wherein said cpn10 is in dehydrated form and in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

Sub A1

20. The kit of Claim 17 or Claim 18, wherein said cpn10 is in tablet or capsule form.

15 21. The kit of Claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10.

22. The kit of Claim 21, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 10-30 mg of cpn10.

20 23. The kit of Claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1-10 MIU of IFN- β .

24. The kit of Claim 23, wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 4-6 MIU of IFN- β .

25

30